United Kingdom Archives

News and Trends 22 Aug 2019

Two-Drug HIV Therapy Given Every 2 Months Proves Effective in Phase III

An experimental HIV therapy being developed by GSK spinoff ViiV Healthcare in partnership with Janssen has proven it is as effective when given every two months as when given once a month. “For the first time since the AIDS epidemic started more than 30 years ago, our study has demonstrated that it is possible to […]

August 22, 2019 - 2 minutesmins - By Clara Rodríguez Fernández

News and Trends 16 Aug 2019

First Potential Chlamydia Vaccine Shows Early Promise

A vaccine targeting the sexually transmitted infection chlamydia, which would be the first of its kind if approved, has proved safe and able to stimulate the immune system in a phase I trial. In the phase I trial, the vaccine was injected into 35 healthy women. Blood samples from the volunteers were then measured to […]

August 16, 2019 - 3 minutesmins - By Jonathan Smith

astrocyte alzheimers disease astronautx blood london

Startup Scout 16 Aug 2019

This Biotech Fights Alzheimer’s Disease by Targeting Support Brain Cells

It’s time to go to London, UK, this week. The UK biotech AstronauTx is developing drugs that could slow the progress of Alzheimer’s disease by aiming at star-shaped cells in the brain called astrocytes. Mission: To develop small molecule drugs targeting astrocytes, whose inflammatory activity is linked to the development of Alzheimer’s disease. Alzheimer’s disease […]

August 16, 2019 - 4 minutesmins - By Jonathan Smith

mallinckrodt regenerative medicine skin graft bioprinting skin

News and Trends 14 Aug 2019

Engineered Skin Shows Potential to Treat Burns in Phase I

Engineered skin tissue, developed as a regenerative medicine by the UK-US pharma company Mallinckrodt, has reduced the need for skin grafts in burns victims in a phase Ib trial. The phase I trial tested Mallinckrodt’s engineered skin treatment in 29 patients suffering from deep second degree burns. Patients with these burns have damage to the […]

August 14, 2019 - 2 minutesmins - By Jonathan Smith

News and Trends 13 Aug 2019

AskBio Acquires Scottish Biotech to Make Gene Therapies More Precise

The US company AskBio has acquired the Edinburgh-based Synpromics to pool their gene therapy technologies and produce inducible gene therapies that target particular organs or cells. AskBio specializes in developing viral vectors that carry gene therapies into cells, such as adeno-associated virus, whereas Synpromics develops DNA sequences called promoters that drive the expression of gene […]

August 13, 2019 - 2 minutesmins - By Jonathan Smith

News and Trends 7 Aug 2019

Late-Stage Clinical Trial Troubles for Dry Eye Disease Drug

A drug developed by the UK company Topivert Pharma has failed to reduce eyeball grittiness sensations in patients with dry eye disease in a phase II/III trial. The trial tested Topivert’s small molecule drug given as eyedrops to 202 patients suffering from dry eye disease, a condition where not enough tears are produced to lubricate […]

August 7, 2019 - 2 minutesmins - By Jonathan Smith

More News! 5 Aug 2019

Phase II Promise for Inhaled Chronic Lung Disease Treatment

A first-in-class inhaled drug developed by the UK biotech Verona Pharma improved lung function in a phase II trial treating the lung condition chronic obstructive pulmonary disease. The 37 patients in the trial had chronic obstructive pulmonary disease (COPD), a common lung condition that involves a tightening of the lung airways and breathlessness. Verona Pharma […]

August 5, 2019 - 2 minutesmins - By Jonathan Smith

atlantic healthcare pouchitis inflammatory bowel disease

More News! 1 Aug 2019

Atlantic Healthcare’s Inflammatory Bowel Disease RNA Drug Fails Phase III

Hopes of seeing an approved treatment for the inflammatory bowel condition pouchitis have been dashed as the UK company Atlantic Healthcare’s RNA drug has proved ineffective in a phase III trial. The trial tested Atlantic Healthcare’s RNA drug alicaforsen as a treatment for patients with pouchitis. Patients with this condition have their colon surgically replaced […]

August 1, 2019 - 2 minutesmins - By Jonathan Smith

inflammatory bowel disease treatment personalized medicine predictimmune

News and Trends 31 Jul 2019

British Biotech Raises €11M to Market Personalized Medicine Test

The UK biotech PredictImmune has raised €11M (£10M) in a Series B fundraising round to commercialize technology to predict the progress of inflammatory bowel disease in newly diagnosed patients. The funds will finance the global launch of PredictSURE IBD, a blood test that can identify patients with the most severe cases of inflammatory bowel disease, […]

July 31, 2019 - 3 minutesmins - By Jonathan Smith

News and Trends 29 Jul 2019

€43M Series C to Launch UK Company’s Home Hemodialysis Kit

Quanta Dialysis Technologies has raised €43.2M ($48M) to fund the commercial launch of a device that makes home hemodialysis more straightforward and economical for kidney failure patients. The UK-based Quanta will use the money to launch its technology in the UK later this year, and also apply for FDA approval. The technology previously obtained a […]

July 29, 2019 - 2 minutesmins - By Jonathan Smith

rnai rna intereference silence therapeutics mallinckrodt

More News! 19 Jul 2019

Mallinckrodt Teams up with UK RNAi Biotech in Deal Worth up to €553M

The UK-based biotech Silence Therapeutics has signed a deal worth up to €553M ($693M) with the UK pharma company Mallinckrodt to develop RNA interference (RNAi) therapies for autoimmune diseases. Mallinckrodt will pay Silence Therapeutics €17.8M ($20M) upfront, and up to €600M ($673M) in developmental milestone payments. In exchange, it will get a license for an […]

July 19, 2019 - 2 minutesmins - By Jonathan Smith

More News! 19 Jul 2019

UK VC Medicxi Closes Third Fund with €400M to Boost European Biotech

The UK-based venture capital investment firm Medicxi has closed its third fund, totaling €400M, to nurture early- and late-stage healthcare biotech companies in Europe. The firm will begin investing in the first beneficiary companies of this fund in the next few months. The big round was raised in just six weeks, and dwarfs Medicxi’s previous […]

July 19, 2019 - 2 minutesmins - By Jonathan Smith

Knowledge hub

Categories

Illuminating biotech in the City of Light: Inside Paris’s thriving ecosystem

ASCO 2025: key highlights in cancer therapeutics

Approaches

Therapeutic areas

New report: Artificial intelligence and the future of antibody discovery

Stem cell therapy: a potential cure for hearing loss?

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

Illuminating biotech in the City of Light: Inside Paris’s thriving ecosystem

ASCO 2025: key highlights in cancer therapeutics

New report: Artificial intelligence and the future of antibody discovery

Stem cell therapy: a potential cure for hearing loss?

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

United Kingdom

Two-Drug HIV Therapy Given Every 2 Months Proves Effective in Phase III

First Potential Chlamydia Vaccine Shows Early Promise

This Biotech Fights Alzheimer’s Disease by Targeting Support Brain Cells

Engineered Skin Shows Potential to Treat Burns in Phase I

AskBio Acquires Scottish Biotech to Make Gene Therapies More Precise

Late-Stage Clinical Trial Troubles for Dry Eye Disease Drug

Phase II Promise for Inhaled Chronic Lung Disease Treatment

Atlantic Healthcare’s Inflammatory Bowel Disease RNA Drug Fails Phase III

British Biotech Raises €11M to Market Personalized Medicine Test

€43M Series C to Launch UK Company’s Home Hemodialysis Kit

Mallinckrodt Teams up with UK RNAi Biotech in Deal Worth up to €553M

UK VC Medicxi Closes Third Fund with €400M to Boost European Biotech

Subscribe to our newsletter to get the latest biotech news!

Illuminating biotech in the City of Light: Inside Paris’s thriving ecosystem

ASCO 2025: key highlights in cancer therapeutics

New report: Artificial intelligence and the future of antibody discovery

Stem cell therapy: a potential cure for hearing loss?

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Illuminating biotech in the City of Light: Inside Paris’s thriving ecosystem

ASCO 2025: key highlights in cancer therapeutics

New report: Artificial intelligence and the future of antibody discovery

Stem cell therapy: a potential cure for hearing loss?

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!